Axogen, Inc. (AXGN)

34.43 -0.01 (-0.03%)

As of 2026-04-02 17:27:28 EST

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.

Traded asNasdaq: AXGN
ISINUS05463X1063
CIK0000805928
LEI—
EIN411301878
Sector—
IndustryElectromedical & Electrotherapeutic Apparatus
CEO—
Employees—
Fiscal Year End1231
Address13631 PROGRESS BLVD., ALACHUA, FL, 32615
Phone(386) 462-6817
Website—
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
AXGNAxogen, Inc.2026-04-02 17:27:2834.43-0.01-0.03
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
AXGN0000805928Axogen, Inc.US05463X1063—411301878Nasdaq3845Electromedical & Electrotherapeutic Apparatus1231MN13631 PROGRESS BLVD.ALACHUAFL32615UNITED STATESUS(386) 462-681713631 PROGRESS BLVD., ALACHUA, FL, 3261513631 PROGRESS BLVD., ALACHUA, FL, 32615LECTEC CORP /MN/—2002-01-01———430,700,00047,199,79751,897,682Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.2026-04-02 17:03:02
This is a preview of the latest data. Subscribe to access the full data.
AXGN Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
AXGN Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2025430,700,000243,910,498130.580451,897,6827,553,89717.0348
2024186,789,502-127,625,256-40.591444,343,7851,137,5392.6328
2023314,414,75892,893,02941.93443,206,246604,3281.4185
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Marc BeganEVP2024423,919—973,992426,29323,3701,847,574
Jens KempChief Marketing Officer2024374,419—973,992376,49621,0641,745,971
Michael DaleCEO, President2024303,163—8,025,000509,49310,2668,847,922
Nir NaorCFO2024475,140—2,073,000477,80122,9413,048,882
Karen ZaderejCEO, President2024439,585—0735,4201,300,6222,475,627
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2025622
2024452
2023428
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue225,208,000187,338,000159,012,000
Cost Of Revenue57,855,00045,361,00031,138,000
Gross Profit167,353,000141,977,000127,874,000
Research And Development Expenses32,885,00027,767,00028,333,000
General And Administrative Expenses44,577,00039,036,00034,943,000
Operating Expenses175,202,000145,264,000149,336,000
Operating Income-7,849,000-3,287,000-21,462,000
Net Income-15,703,000-9,964,000-21,716,000
Earnings Per Share Basic-0.34-0.23-0.51
Earnings Per Share Diluted-0.34-0.23-0.51
Weighted Average Shares Outstanding Basic46,050,26644,257,75442,878,543
Weighted Average Shares Outstanding Diluted46,050,26644,257,75442,878,543
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents35,548,00027,554,00031,024,000
Marketable Securities Current5,980,0005,928,0000
Accounts Receivable26,169,00024,105,00025,147,000
Inventories42,373,00033,183,00023,020,000
Non Trade Receivables———
Other Assets Current———
Total Assets Current120,422,00099,217,00088,004,000
Marketable Securities Non Current———
Property Plant And Equipment———
Other Assets Non Current670,000562,000432,000
Total Assets Non Current101,265,000104,511,000108,823,000
Total Assets221,687,000203,728,000196,827,000
Accounts Payable2,888,0008,008,00011,774,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current———
Total Liabilities Current23,556,00030,610,00030,430,000
Long Term Debt48,387,00047,496,00046,603,000
Other Liabilities Non Current141,00094,000—
Total Liabilities Non Current69,284,00069,211,00070,732,000
Total Liabilities92,840,00099,821,000101,162,000
Common Stock472,000441,000431,000
Retained Earnings-306,963,000-291,260,000-281,296,000
Accumulated Other Comprehensive Income———
Total Shareholders Equity128,847,000103,907,00095,665,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization6,660,0006,467,0004,218,000
Share Based Compensation Expense30,112,00015,906,00014,418,000
Other Non Cash Income Expense00-56,000
Change In Accounts Receivable2,464,000-392,0002,691,000
Change In Inventories9,190,00010,163,0006,054,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-7,158,000125,0006,509,000
Change In Other Liabilities47,000——
Cash From Operating Activities812,0004,535,000-5,716,000
Purchases Of Marketable Securities13,723,0005,773,00010,203,000
Sales Of Marketable Securities14,000,000044,374,000
Acquisition Of Property Plant And Equipment3,745,0003,101,00013,872,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-5,317,000-10,297,00019,253,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock10,531,0002,300,0001,964,000
Repurchase Of Common Stock———
Issuance Of Long Term Debt——0
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities10,499,0002,290,0001,954,000
Change In Cash5,994,000-3,472,00015,491,000
Cash At End Of Period35,548,00027,554,00031,024,000
Income Taxes Paid———
Interest Paid6,811,0007,301,0001,944,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-0.34-0.23-0.51
Price To Earnings Ratio-96.2647-71.6522-13.3922
Earnings Growth Rate47.8261-54.902-26.087
Price Earnings To Growth Ratio-2.01281.30510.5134
Book Value Per Share2.7982.34782.2311
Price To Book Ratio11.69787.01943.0613
Ebitda-1,341,0004,709,000-14,663,000
Enterprise Value1,520,064,206.18749,309,785.92308,439,448.69
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.37550.45710.4871
Capital Expenditures———
Free Cash Flow———
Return On Equity-0.1219-0.0959-0.227
One Year Beta0.63511.53111.7319
Three Year Beta1.09721.39011.3995
Five Year Beta1.21871.30251.276
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Hartley Lindsey MarieCFO2026-03-164,000A59,276
Hartley Lindsey MarieCFO2026-03-161,574D57,702
Hartley Lindsey MarieCFO2026-03-165,000A62,702
Hartley Lindsey MarieCFO2026-03-161,968D60,734
Hartley Lindsey MarieCFO2026-03-164,000A4,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
F&V Capital Management, LLC2025-12-315,793,000176,99532.7297
GOLDMAN SACHS GROUP INC2025-12-3115,663,236478,55932.73
Rockefeller Capital Management L.P.2025-12-3176,7192,34432.7299
Caitong International Asset Management Co., Ltd2025-12-3152,4331,60232.7297
Invesco Ltd.2025-12-316,197,261189,34532.73
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Global X Funds2026-01-31Global X Russell 2000 ETFRSSL20,074699,578.90.0505
INVESCO EXCHANGE-TRADED FUND TRUST2026-01-31Invesco RAFI US 1500 Small-Mid ETFPRFZ31,1161,084,392.60.0405
EXCHANGE TRADED CONCEPTS TRUST2026-01-31ROBO Global(R) Healthcare Technology and Innovation ETFHTEC31,8971,111,610.452.0222
OLD WESTBURY FUNDS INC2026-01-31Old Westbury Total Equity FundOWTEX14,037489,189.450.0445
VANGUARD EXPLORER FUND2026-01-31Admiral SharesVEXRX493,18017,187,3230.0827
This is a preview of the latest data. Subscribe to access the full data.